Search Results for “EC” – Page 283 – media

New Testing Strips to Make Rapid Antigen Testing as Powerful as PCR Testing

During the onset of the pandemic, individuals experiencing symptoms had to endure lengthy queues for lab-based PCR testing and then wait around two days for the results, to confirm if they were infected with the COVID-19 virus. This process was not only inconvenient but also involved complex and costly logistics, contributing to testing delays and increasing the risk of spreading the disease. Now, a newly developed biosensing technology enables the creation of gene test strips that can match the quality of traditional lab-based tests. The new technology developed by a team of biomedical engineers at UNSW Sydney (Sydney, Australia) offers test strips that are as accurate as lab-based PCR tests, with the added advantage of quick, on-site disease detection. Described by the researchers as having “PCR in your pocket,” this advancement holds potential for broad applications in biomedical and environmental diagnostics across various sectors, including food, agriculture, and biosafety management. ...
- Source: drugdu
- 86
- March 8, 2024
ViiV Healthcare Reveals Positive Results from Phase I Trial for a Potential Longer-Acting HIV Treatment

Don Tracy, Associate Editor Novel formulation of cabotegravir (CAB-ULA) allows for dosing intervals of at least four months.Image Credit: Adobe Stock Images/alexskopjeViiV Healthcare has announced promising results from a Phase I study on a new formulation of cabotegravir (Apretude), known as cabotegravir ultra long-acting (CAB-ULA) for HIV pre-exposure prophylaxis (PrEP). Findings suggested that CAB-ULA is well-tolerated and has a pharmacokinetic profile supportive of extended dosing intervals. According to a company press release, the formulation allows dosing intervals of four months, resulting in a reduction of clinical visits for HIV patients.1 “The HIV community has told us of their desire for longer-acting medicines that can help alleviate the burden of daily treatment,” said Kimberly Smith, MD, MPH, head of research and development, ViiV Healthcare, in the press release. “ViiV Healthcare is a pioneer and leader in the development of long-acting HIV medicine, having already brought innovations through injectable therapies to the ...
- Source: drugdu
- 76
- March 8, 2024
Gilead Sciences Signs Yet Another R&D Alliance for Multi-Target Cancer Therapies

Gilead Sciences’ partnership with Merus could yield novel antibody drugs capable of binding to three targets simultaneously. The alliance follows a collaboration that Gilead started last year with Tentarix Biotherapeutics, a startup also developing antibodies that bind to multiple targets. By FRANK VINLUAN Bispecific antibody drugs have shown that binding to two targets simultaneously can be a powerful and effective way to treat cancer. Binding to three targets could be even better, and Gilead Sciences is turning to biotech company Merus to find out. Under the collaboration agreement announced Wednesday, Gilead is paying Merus $56 million up front and making a $25 million equity investment in the biotech. Netherlands-based Merus focuses on developing antibody therapies that bind to two or three targets at the same time. This capability could block multiple receptors that drive tumor growth and survival. It could also coax a patient’s immune cells to kill tumors. So ...
- Source: drugdu
- 98
- March 8, 2024
Henlius’ Trastuzumab Plots Southeast Asia Expansion, to Enter Thailand and Philippines

Recently, Henlius’ self-developed and manufactured HANQUYOU (trastuzumab, trade names: Zercepac® in Europe, Tuzucip® and Trastucip® in Australia) has been approved for marketing in Thailand and the Philippines under the trade names of TRAZHER® and Hertumab®, respectively, for the treatment of HER2-positive breast cancer and gastric cancer. Up to now, HANQUYOU has been successfully approved in Southeast Asian countries, including Singapore and Cambodia, and in a total of more than 40 countries and regions. Breast cancer is the most prevalent malignancy in Southeast Asia, with nearly 170,000 new cases of breast cancer in the region in 2022. About 15% to 20% of breast tumours are HER2-positive breast cancers. On the other hand, the reported rates of HER2 positivity in patients with gastric cancer range from 12% to 23%. Trastuzumab has long been a cornerstone of therapy for the treatment of HER2-positive breast and gastric cancers, and has been included as a ...
- Source: drugdu
- 127
- March 8, 2024
Researchers aim to ensure future AI healthcare monitoring systems are free of gender bias

The project will train a newly developed AI system on data collected from participating men and women Researchers from the University of Glasgow’s James Watt School of Engineering are aiming to ensure that artificial intelligence (AI)-based healthcare monitoring systems in the future are free of gender bias, to improve care for both men and women. For 18 months, the project will examine the potential for gender bias in healthcare AI and discover ways to ensure that AI-supported treatment remains equitable. The use of cutting-edge sensors is currently being investigated to track the rhythms of patients’ hearts and lungs without requiring them to wear monitoring devices or be recorded on video cameras. The team aims to address and ensure that its AI component is properly trained and capable of making the correct judgements without bias towards one gender of patients. Supported by £8,200 in funding from the Université Paris Dauphine-PSL’s Women ...
- Source: drugdu
- 72
- March 8, 2024
The United States prohibits the flow of data to China and other countries, and clinical trials in the United States are challenged again?

Recently, U.S. President Joe Biden officially signed the “Executive Order on Preventing Countries of Concern from Obtaining Extensive Sensitive Personal Data of U.S. Citizens and U.S. Government-Related Data,” calling for measures to be taken to prevent “bad actors” and “countries of concern” from abusing data related to the United States. Various types of data about citizens, including genomic data, biometric data, personal health data, geolocation data, financial data and other types of personally identifiable information. The executive order may pose new challenges to Chinese life sciences companies operating in the United States. The order requires the Departments of Justice, Homeland Security, Health and Human Services, Veterans Affairs and other agencies to take a variety of actions over the next 12 months, including: Ministry of Justice: Regulations will be enacted to govern cross-border transfers of large-scale data related to genomics, biometrics, personal health data, geolocation and the above areas, including a ...
- Source: drugdu
- 103
- March 8, 2024
Drugmakers submit counteroffers to US Medicare pricing negotiations

The US Department of Health and Human Services (HHS), as part of the Centers for Medicare and Medicaid Services (CMS), has announced that all ten pharmaceutical manufacturers taking part in the Medicare drug price negotiations have submitted counteroffers. The announcement comes after the HHS sent initial offers on 1 February in an ongoing effort to lower drug prices in the US as part of the Inflation Reduction Act (IRA) and negotiations will continue over the next several months. First selected last August, the ten medicines subject to the first round of Medicare pricing negotiations included therapies for diabetes, heart failure, immunological disorders and cancer, as well as anticoagulants. The medicines selected included Bristol Myers Squibb/Pfizer’s Eliquis (apixaban), Novartis’ Entresto (valsartan/sacubitril), AstraZeneca’s Farxiga (dapagliflozin), AbbVie/Johnson & Johnson’s Imbruvica (ibrutinib), Eli Lilly/Boehringer Ingelheim’s Jardiance (empagliflozin), and Johnson & Johnson’s Stelara (ustekinumab) and Xarelto (rivaroxaban). According to the HHS, collectively, the drugs were ...
- Source: drugdu
- 75
- March 8, 2024
Noninvasive, Low-Cost Test Accurately Diagnoses Oral Cancer in 30 Minutes

Oral cancer comprises about 90% of head and neck cancer (HNC), which ranks as the seventh most common type of malignancy globally. HNC constitutes roughly 5% of all cancer cases worldwide, with approximately 640,000 new cases annually, leading to around 350,000 deaths. Its incidence is particularly increasing in developing countries. These cancers predominantly affect socioeconomically disadvantaged populations and underserved communities. Diagnosing oral cancers and precancerous mouth lesions early and accurately presents significant challenges. Traditional biopsy methods are not only expensive and invasive, causing stress and potential complications for patients, but also unfeasible for repeated screenings of the same lesion. Now, researchers have developed a noninvasive, affordable test for detecting oral cancer, monitoring precancerous lesions, and determining the need for a biopsy. The findings of the study by a team of researchers, led by Case Western Reserve University (Cleveland, OH, USA), are based on a novel scoring system that assesses the ...
- Source: drugdu
- 84
- March 7, 2024
FDA Approves AbbVie’s Juvederm Voluma XC for the Treatment of Moderate to Severe Temple Hollowing

Don Tracy, Associate Editor This marks the first time that a hyaluronic acid dermal filler has received FDA approval for temple hollowing. Allergan Aesthetics, an AbbVie company, announced that the FDA has approved Juvéderm Voluma XC to treat moderate to severe temple hollowing in adults over 21 years of age. According to the company, the medication has the ability to yield results that last up to 13 months with peak treatment, with approximately 80% of test subjects reporting satisfaction with the outcomes. With this regulatory action, Juvéderm Voluma becomes the first hyaluronic acid (HA) dermal filler indicated for moderate to severe temple hollowing to be approved by the FDA.1 “The approval of Juvéderm Voluma XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs,” said Carrie Strom, president, Allergan Aesthetics, SVP, AbbVie, in a press release. “This is the first US FDA approval of ...
- Source: drugdu
- 120
- March 7, 2024
FDA Approves Sandoz Biosimilars for Two Blockbuster Amgen Bone Drugs

Sandoz drugs Jubbonti and Xgeva are approved for use in all indications covered by the Amgen products, Prolia and Xgeva. But no launch date is planned yet, due to ongoing patent litigation between the two companies. By FRANK VINLUAN A blockbuster Amgen antibody that treats bone conditions is set to face its first biosimilar competition. The FDA on Tuesday approved two Sandoz drugs as interchangeable with and approved for all uses of the Amgen products. The Amgen antibody, denosumab, is marketed as Prolia for the treatment of osteoporosis. A different dose of the antibody is marketed as Xgeva for preventing bone problems in multiple myeloma patients as well as those whose solid tumors have metastasized to the bones. Sandoz’s biosimilar for the osteoporosis indication will be marketed under the name Jubbonti. For cancer, the Sandoz product will be called Wyost. The Amgen and Sandoz drugs work by binding to a ...
- Source: drugdu
- 131
- March 7, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.